1995
DOI: 10.1172/jci118062
|View full text |Cite
|
Sign up to set email alerts
|

Lipoxygenase contributes to the oxidation of lipids in human atherosclerotic plaques.

Abstract: IntroductionOxidized LDL is present in human atherosclerotic lesions, but the mechanisms responsible for oxidation in In the last decade strong evidence has accumulated supporting the concept that oxidative processes, acting on the lipids and proteins of LDL in the vessel wall, participate in the progression of atherosclerotic disease ( 1-4). Evidence from in situ studies has demonstrated that oxidized LDL, macrophages, and 15-lipoxygenase colocalize within human atherosclerotic lesions (5). We therefore cho… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

4
144
1
4

Year Published

1996
1996
2014
2014

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 240 publications
(153 citation statements)
references
References 36 publications
4
144
1
4
Order By: Relevance
“…2). The presence of specific LOX products in early atherosclerotic lesions indicates that LOX catalysis occurs in vivo, although precise control mechanisms remain to be elucidated (19)(20)(21). Herein, inclusion of the metal chelator DTPA prevents secondary nonenzymatic generation of additional lipid radicals.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…2). The presence of specific LOX products in early atherosclerotic lesions indicates that LOX catalysis occurs in vivo, although precise control mechanisms remain to be elucidated (19)(20)(21). Herein, inclusion of the metal chelator DTPA prevents secondary nonenzymatic generation of additional lipid radicals.…”
Section: Discussionmentioning
confidence: 99%
“…15-and 12͞15-LOXs play a central role in vascular disease, because (i) 15-LOX mRNA, protein, and lipid products are found in atheroma, (ii) inhibition of 15-LOX prevents atherosclerosis in rabbits, and (iii) functional inactivation of the 12͞15-LOX gene slows down aortic lipid deposition in apo E-deficient mice, and inhibits streptozotocin-induced diabetes (19)(20)(21)(22)(23)(24)(25). Furthermore, in vivo, 12͞15-LOX expression is required for neointimal thickening in ballooninjured rat aortae (26,27).…”
Section: ͞15-lipoxygenase (Lox) Activity Is Elevated In Vascular DImentioning
confidence: 99%
“…As lipids are taken up into the vascular wall, they undergo oxidative modifications [10]. Several studies support a lipoxygenase-mediated oxidation of low density lipoproteins (LDL) [30,31], mainly mediated trough the 15-lipoxygenase (15-LO) pathway [32]. However, recent findings have indicated an absence of 15-LO expression within atherosclerotic lesions [33], hence questioning its role as a driver of LDL oxidation in vivo.…”
Section: Lipid Retention and Modificationmentioning
confidence: 99%
“…1992). Oxidation may proceed more rapidly after the introduction of seeding hydroperoxides into the LDL particle by lipoxygenase enzymes (Folcik et al 1995). Regardless of the mechanisms involved, oxidation of polyunsaturated fatty acids within LDL leads to the formation of short-chain aldehydes such as malondialdehyde and 4-hydroxynonenal, which react with key lysine residues on the apoB molecule (Steinberg et al 1989).…”
Section: Susceptibility Of Ldl To Oxidationmentioning
confidence: 99%